Krystal Biotech/KRYS

$160.79

2.83%
-
1D1W1MYTD1YMAX

About Krystal Biotech

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.

Ticker

KRYS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Krish Krishnan

Employees

229

Headquarters

Pittsburgh, United States

Krystal Biotech Metrics

BasicAdvanced
$4.5B
Market cap
84.48
P/E ratio
$1.88
EPS
0.89
Beta
-
Dividend rate
$4.5B
0.88985
$189.97
$93.95
329K
12.655
12.423
71.797
8.25%
8.87%
8.78%
84.485
47.325
5.675
5.681
135.68%

What the Analysts think about Krystal Biotech

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
17.54% upside
High $208.00
Low $153.00
$160.79
Current price
$189.00
Average price target

Krystal Biotech Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
1.99% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$45M
7.36%
Net income
$900K
-89.53%
Profit margin
1.99%
-90.25%

Krystal Biotech Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 79.61%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.25
$2.79
$0.30
$0.03
-
Expected
-$0.74
-$0.29
-$0.43
$0.15
$0.62
Surprise
69.68%
-1,075.52%
-170.59%
-79.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Krystal Biotech stock?

Krystal Biotech (KRYS) has a market cap of $4.5B as of May 30, 2024.

What is the P/E ratio for Krystal Biotech stock?

The price to earnings (P/E) ratio for Krystal Biotech (KRYS) stock is 84.48 as of May 30, 2024.

Does Krystal Biotech stock pay dividends?

No, Krystal Biotech (KRYS) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Krystal Biotech dividend payment date?

Krystal Biotech (KRYS) stock does not pay dividends to its shareholders.

What is the beta indicator for Krystal Biotech?

Krystal Biotech (KRYS) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Krystal Biotech stock price target?

The target price for Krystal Biotech (KRYS) stock is $189, which is 17.54% above the current price of $160.79. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Krystal Biotech stock

Buy or sell Krystal Biotech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing